Isoprenoid biosynthesis as a drug target: Bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin

Journal of Medicinal Chemistry

Volumn 49, Issue 25, 2006, Pages 7331-7341

  Leon, Annette ^a   Liu, Lei ^a   Yang, Yan ^a   Hudock, Michael P ^a   Hall, Patrick ^a   Yin, Fenglin ^a   Studer, Danielle ^b   Puan, Kia Joo ^c   Morita, Craig T ^c   Oldfield, Eric ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHLORAMPHENICOL; FOSMIDOMYCIN; GERANYLTRANSFERASE; ISOPRENOID; KANAMYCIN; N [METHYL (4 PHENYLBUTYL)] 3 AMINOPROPYL 1 HYDROXY 1,1 BISPHOSPHONATE; NEOMYCIN; NOVOBIOCIN; STREPTOMYCIN; TETRACYCLINE;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CELL ACTIVITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG POTENTIATION; ESCHERICHIA COLI K 12; IC 50; NONHUMAN;

ANTI-BACTERIAL AGENTS; CLUSTER ANALYSIS; DIPHOSPHONATES; DRUG SYNERGISM; ESCHERICHIA COLI K12; FOSFOMYCIN; GENE EXPRESSION; GERANYLTRANSTRANSFERASE; MODELS, MOLECULAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TERPENES;

EID: 33845473042     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060492b     Document Type: Article

References (47)

1. Projan, S. J.; Shlaes, D. M. Antibacterial drug discovery: Is it all downhill from here? Clin. Microbiol. Infect. 2004, 10, 18-22.
2. Apfel, C. M.; Takacs, B.; Fountoulakis, M.; Stieger, M.; Keck, W. Use of genomics to identify bacterial undecaprenyl pyrophosphate synthetase: Cloning, expression, and characterization of the essential uppS gene. J. Bacteriol. 1999, 181, 483-492.
3. Kato, J.; Fujisaki, S.; Nakajima, K.; Nishimura, Y.; Sato, M.; Nakano, A. The Escherichia coli homologue of yeast RER2t2, a key enzyme of dolichol synthesis, is essential for carrier lipid formation in bacterial cell wall synthesis. J. Bacteriol. 1999, 181, 2733-2738.
4. Li, H.; Huang, J.; Jiang, X.; Seefeld, M.; McQueney, M.; Macarron, R. The effect of triton concentration on the activity of undecaprenyl pyrophosphate synthase inhibitors. J. Biomol. Screen. 2003, 8, 712-715.
5. Liu, G. Y.; Essex, A.; Buchanan, J. T.; Datta, V.; Hoffman, H. M.; Bastian, J. F.; Fierer, J.; Nizet, V. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J. Exp. Med. 2005, 202, 209-215.
6. Kuntz, L.; Tritsch, D.; Grosdemange-Billiard, C.; Hemmerlin, A.; Willem, A.; Bach, T. J.; Rohmer, M. Isoprenoid biosynthesis as a target for antibacterial and antiparasitic drugs: Phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase. Biochem. J. 2005, 386, 127-135.
7. Wilding, E. I.; Kim, D. Y.; Bryant, A. P.; Gwynn, M. N.; Lunsford, R. D.; McDevitt, D.; Myers, J. E., Jr.; Rosenberg, M.; Sylvester, D.; Stauffacher, C. V.; Rodwell, V. W. Essentiality, expression, and characterization of the class II 3-hydroxy-3-methylglutaryl coenzyme A reductase of Staphylococcus aureus. J. Bacteriol. 2000, 182, 5147-5152.
8. Sacchettini, J. C., Poulter, C. D. Creating isoprenoid diversity. Science 1997, 277, 1788-1789.
9. Rohmer, M. The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants. Nat. Prod. Rep. 1999, 16, 565-574.
10. Jomaa, H.; Wiesner, J.; Sanderbrand, S.; Altincicek, B.; Weidemeyer, C.; Hintz, M.; Turbachova, I.; Eberl, M.; Zeidler, J.; Lichtenthaler, H. K.; Soldati, D.; Beck, E. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 1999, 285, 1502-1503.
11. Liu, G. Y.; Doran, K. S.; Lawrence, T.; Turkson, N.; Puliti, M.; Tissi, L.; Nizet, V. Sword and shield: Linked group B streptococcal beta-hemolysin/cytolysin and carotenoid pigment function to subvert host phagocyte defense. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 14491-14496.
12. Neu, H. C.; Kamimura, T. Synergy of fosmidomycin (FR-31564) and other antimicrobial agents. Antimicrob. Agents Chemother. 1982, 22, 560-563.
13. Wiesner, J.; Henschker, D.; Hutchinson, D. B.; Beck, E.; Jomaa, H. In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob. Agents Chemother. 2002, 46, 2889-2894.
14. Borrmann, S.; Adegnika, A. A.; Moussavou, F.; Oyakhirome, S.; Esser, G.; Matsiegui, P.-B.; Ramharter, M.; Lundgren, I.; Kombila, M.; Issifou, S.; Hutchinson, D.; Wiesner, J.; Jomaa, H.; Kremsner, P. G. Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 2005, 49, 3749-3754.
15. Urbina, J. A.; Lazardi, K.; Marchan, E.; Visbal, G.; Aguirre, T.; Piras, M. M.; Piras, R.; Maldonado, R. A.; Payares, G.; de Souza, W. Mevinolin (Lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: In vitro and in vivo studies. Antimicrob. Agents Chemother. 1993, 37, 580-591.
16. Martin, M. B.; Grimley, J. S.; Lewis, J. C.; Heath, H. T., III; Bailey, B. N.; Kendrick, H.; Yardley, V.; Caldera, A.; Lira, R.; Urbina, J. A.; Moreno, S. N.; Docampo, R.; Croft, S. L.; Oldfield, E. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: A potential route to chemotherapy. J. Med. Chem. 2001, 44, 909-916.
17. Benaim, G.; Sanders, J. M.; Garcia-Marchan, Y.; Colina, C.; Lira, R.; Caldera, A. R.; Payares, G.; Sanoja, C.; Burgos, J. M.; Leon-Rossell, A.; Concepcion, J. L.; Schijman, A. G.; Levin, M.; Oldfield, E.; Urbina, J. A. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J. Med. Chem. 2006, 49, 892-899.
18. Montalvetti, A.; Bailey, B. N.; Martin, M. B.; Severin, G. W.; Oldfield, E.; Docampo, R. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J. Biol. Chem. 2001, 276, 33930-33937.
19. Szabo, C. M.; Matsumura, Y.; Fukura, S.; Martin, M. B.; Sanders, J. M.; Sengupta, S.; Cieslak, J. A.; Loftus, T. C.; Lea, C. R.; Lee, H. J.; Koohang, A.; Coates, R. M.; Sagami, H.; Oldfield, E. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: A potential route to new bone antiresorption and antiparasitic agents. J. Med. Chem. 2002, 445, 2185-2196.
20. Martin, M. B.; Sanders, J. M.; Kendrick, H.; de Luca-Fradley, K.; Lewis, J. C.; Grimley, J. S.; Van Brussel, E. M.; Olsen, J. R.; Meints, G. A.; Burzynska, A.; Kafarski, P.; Croft, S. L.; Oldfield, E. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J. Med. Chem. 2002, 45, 2904-2914.
21. Sanders, J. M.; Gomez, A. O.; Mao, J.; Meints, G. A.; Van Brussel, E. M.; Burzynska, A.; Kafarski, P.; Gonzalez-Pacanowska, D.; Oldfield, E. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J. Med. Chem. 2003, 46, 5171-5183.
22. Ghosh, S.; Chan, J. M.; Lea, C. R.; Meints, G. A.; Lewis, J. C.; Tovian, Z. S.; Flessner, R. M.; Loftus, T. C.; Burchhaus, I.; Kendrick, H.; Croft, S. L.; Kemp, R. G.; Kobayashi, S.; Nozaki, T.; Oldfield, E. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J. Med. Chem. 2004, 47, 175-187.
23. Sanders, J. M.; Ghosh, S.; Chan, J. M.; Meints, G.; Wang, H.; Raker, A. M.; Song, Y.; Colantino, A.; Burzynska, A.; Kafarski, P.; Morita, C. T.; Oldfield, E. Quantitative structure-activity relationships for γδ T cell activation by bisphosphonates. J. Med. Chem. 2004, 47, 375-384.
24. Ling, Y.; Sahota, G.; Odeh, S.; Chan, J. M.; Araujo, F. G.; Moreno, S. N.; Oldfield, E. Bisphosphonate inhibitors of Toxoplasma gondi growth: In vitro, QSAR, and in vivo investigations. J. Med. Chem. 2005, 48, 3130-3140.
25. Kotsikorou, E.; Song, Y.; Chan, J. M.; Faelens, S.; Tovian, Z.; Broderick, E.; Bakalara, N.; Docampo, R.; Oldfield, E. Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase. J. Med. Chem. 2005, 48, 6128-6129.
26. Bauer, A. W.; Kirby, W. M.; Sherris, J. C.; Turck, M. Antibiotic susceptibility testing by standardized single disk method. Am. J. Clin. Pathol. 1966, 45, 493-497.
27. Kaneda, K.; Kuzuyama, T.; Takagi, M.; Hayakawa, Y.; Seto, H. An unusual isopentenyl diphosphate isomerase found in the mevalonate pathway gene cluster from Streptomyces sp. strain CL190. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 932-937.
28. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard, 5th ed.; NCCLS document M7-A5; National Committee for Clinical Laboratory Standards: Wayne, PA, 2000.
29. American Type Culture Collection. MTT Cell Proliferation Assay. ATCC, Manassas, VA. http://www.atcc.org/documents/odf/20-1010.k.pdf, 2001 [online].
30. Rieger, C. E.; Lee, J.; Turnbull, J. L. A continuous spectrophotometric assay for aspartate transcarbamylase and ATPases. Anal. Biochem. 1997, 246, 86-95.
31. Eliopoulos, G. M.; Moellering, R. C. Antimicrobial combinations. In Antibiotics in Laboratory Medicine, 4th ed.; Lorian, V., Ed.; Williams & Wilkins Publising Co.: Baltimore, 1998; pp 330-396.
32. Singh, P. K.; Tack, B. F.; McCray, P. B.; Welsh, M. J. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am. J. Physiol. Lung Cell Mol. Physiol. 2000, 279, 799-805.
33. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). EUCAST Definitive Document E. Def 1.2, May 2000: Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin. Microbiol. Infect. 2000, 6, 503-508.
34. Suhnel, J. Zero interaction response surfaces, interaction functions and difference response surfaces for combinations of biologically active agents. Arzneim.-Forsch. 1992, 42, 1251-1258.
35. Berenbaum, M. C. What is synergy? Pharmacol. Rev. 1989, 41, 93-141.
36. Tel-Test, Inc. 2004. RNA STAT-60. Total RNA/mRNA isolation reagent. Tel-Test, Inc., Friendswood, TX. http://www.isotexdiagnostics.com/rna_stat- 60_reagent.html [online].
37. Affymetrix, Inc. 2002. GeneChip E. coli antisense genome array technical manual. Affymetrix, Inc., Santa Clara, CA. http://www.affymetrix.com/support/ technical/manuals.affx [online].
38. Li, C.; Wong, W. H. Model-based analysis of oligonucleotide arrays: Model validation, design issues and standard error application. Genome Biology 2001, 2:research0032.1-0032.11 [online].
39. Chu, T.; Weir, B.; Wolfinger, R. A systematic statistical linear modeling approach to oligonucleotide array experiments. Math. Biosci. 2002, 176, 35-51.
40. Takagi, M.; Kuzuyama, T.; Takahashi, S.; Seto, H. A gene cluster for the mevalonate pathway from Streptomyces sp. Strain CL190. J. Bacteriol. 2000, 182, 4153-4157.
41. Widler, L.; Jaeggi, K. A.; Glatt, M.; Muller, K.; Bachmann, R.; Bisping, M.; Born, A. R.; Cortesi, R.; Guiglia, G.; Jeker, H.; Klein, R.; Ramseier, U.; Schmid, J.; Schreiber, G.; Seltenmeyer, Y.; Green, J. R. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J. Med. Chem. 2002, 45, 3721-3738.
42. Kotsikorou, E.; Oldfield, E. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents. J. Med. Chem. 2003, 46, 2932-2944.
43. Buckner, F. E.; Griffin, J. H.; Wilson, A. J.; Van Voorhis, W. C. Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob. Agents Chemother. 2001, 45 (4), 1210-1215.
44. Shaw, K. J.; Miller, N.; Liu, X.; Lerner, D.; Wan, J.; Bittner, A.; Morrow, B. J. Comparison of the changes in global gene expression of Escherichia coli induced by four bactericidal agents. J. Mol. Microbiol. Biotechnol. 2003, 5, 105-122.
45. Takahashi, S.; Kuzuyama, T.; Watanabe, H.; Seto, H. A 1-deoxy-D-xylulose 5-phosphate reductoisomerase catalyzing the formation of 2-C-methyl-D-erythriol 4-phosphate in an alternative nonmevalonate pathway for terpenoid biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9879-9884.
46. Fujisaki, S.; Takahashi, I.; Hara, H.; Horiuchi, K.; Nishino, T.; Nishimura, Y. Disruption of the structural gene for farnesyl diphosphate synthase in Escherichia coli. J. Biochem. (Tokyo) 2005, 137, 395-400.
47. Hahn, F. M.; Hurlburt, A. P.; Poulter, C. D. Escherichia coli open reading frame 696 is idi, a nonessential gene encoding isopentenyl diphosphate isomerase. J. Bacteriol. 1999, 181, 4499-4504.